Extending it to clinical settings, a cohort of primary and metastatic melanoma human biopsies bearing BRAFV600E/K gene mutation showed a higher immunoexpression of Cav3.1 compared with a BRAF wild-type melanoma cohort (Table 1; Figure 1B) [20]. The gene discussed is BRAF; the disease is melanoma.